JP2005325139A - 注意欠損/多動障害治療用の医薬を製造するためのトモキセチンの使用 - Google Patents
注意欠損/多動障害治療用の医薬を製造するためのトモキセチンの使用 Download PDFInfo
- Publication number
- JP2005325139A JP2005325139A JP2005232408A JP2005232408A JP2005325139A JP 2005325139 A JP2005325139 A JP 2005325139A JP 2005232408 A JP2005232408 A JP 2005232408A JP 2005232408 A JP2005232408 A JP 2005232408A JP 2005325139 A JP2005325139 A JP 2005325139A
- Authority
- JP
- Japan
- Prior art keywords
- hyperactivity disorder
- use according
- tomoxetine
- disorder
- hyperactivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
【解決手段】 注意欠損/多動障害治療用の医薬を製造するためのトモキセチンの使用法、ならびに注意欠損/多動障害を治療するためのトモキセチンの使用法を提供する。
【選択図】なし
Description
注意欠損/多動障害の診断基準
A.(1)または(2):
不注意
(a)細部に対する緻密な注意が払えないか、学業、仕事、または他の活動において不注意な間違いをすることが多い。
(b)作業や遊び活動に注意を持続することが困難なことが多い。
(c)直接話している時に聞いていないようなことが多い。
(d)指示に従わず、学業、雑用、または職場での職務を成し遂げられないことが多い(抵抗行動や指示が理解できないためではなく)。
(e)仕事および活動を計画することが困難なことが多い。
(f)持続的な精神的努力を要する仕事(学業や宿題のような)に携わることを避ける、嫌う、または嫌がることが多い。
(g)仕事や活動に必要なもの(例えば、玩具、宿題、鉛筆、本、または道具)をなくすことが多い。
(h)外部刺激によって容易に気が散ることが多い。
(i)日々の活動において物忘れすることが多い。
多動
(a)手や足をいじりまわしたり、席でもじもじすることが多い。
(b)教室や座っていることが求められる他の状況で席を離れることが多い。
(c)不適切な状況で過度に走り回ったりよじ登ったりすることが多い(青春期または成人において;落ち着きがないという主観的感覚に限ってよい)。
(d)静かに余暇活動を行ったり、遊んだりすることが困難であることが多い。
(e)「絶えず活動している」ことが多いかまたは「モーターで動いている」かのように行動することが多い。
(f)過剰にしゃべることが多い。
衝動性
(g)質問が終わる前に突然答えだすことが多い。
(h)順番を待つことが困難なことが多い。
(i)他人に強いたり、遮ったりすることが多い(例えば、会話やゲームに口出しする)。
Claims (16)
- 注意欠損/多動障害の治療を必要とする患者に対しトモキセチンの有効量を投与することを含む該障害の治療用の医薬を製造するためのトモキセチンの使用。
- 注意欠損/多動障害の主として不注意型を治療するものである請求項1に記載の使用。
- 注意欠損/多動障害の主として多動−衝動型を治療するものである請求項1に記載の使用。
- 注意欠損/多動障害の複合型を治療するものである請求項1に記載の使用。
- 患者が成人である請求項1に記載の使用。
- 注意欠損/多動障害の主として不注意型を治療するものである請求項5に記載の使用。
- 注意欠損/多動障害の主として多動−衝動型を治療するものである請求項5に記載の使用。
- 注意欠損/多動障害の複合型を治療するものである請求項5に記載の使用。
- 患者が青年期である請求項1に記載の使用。
- 注意欠損/多動障害の主として不注意型を治療するものである請求項9に記載の使用。
- 注意欠損/多動障害の主として多動−衝動型を治療するものである請求項9に記載の使用。
- 注意欠損/多動障害の複合型を治療するものである請求項9に記載の使用。
- 患者が子供である請求項1に記載の使用。
- 注意欠損/多動障害の主として不注意型を治療するものである請求項13に記載の使用。
- 注意欠損/多動障害の主として多動−衝動型を治療するものである請求項13に記載の使用。
- 注意欠損/多動障害の複合型を治療するものである請求項13に記載の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/371,341 US5658590A (en) | 1995-01-11 | 1995-01-11 | Treatment of attention-deficit/hyperactivity disorder |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8521732A Division JPH10512262A (ja) | 1995-01-11 | 1996-01-04 | 注意欠陥/多動障害の治療方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005325139A true JP2005325139A (ja) | 2005-11-24 |
Family
ID=23463572
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8521732A Withdrawn JPH10512262A (ja) | 1995-01-11 | 1996-01-04 | 注意欠陥/多動障害の治療方法 |
JP2005232408A Pending JP2005325139A (ja) | 1995-01-11 | 2005-08-10 | 注意欠損/多動障害治療用の医薬を製造するためのトモキセチンの使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8521732A Withdrawn JPH10512262A (ja) | 1995-01-11 | 1996-01-04 | 注意欠陥/多動障害の治療方法 |
Country Status (28)
Country | Link |
---|---|
US (1) | US5658590A (ja) |
EP (1) | EP0721777B1 (ja) |
JP (2) | JPH10512262A (ja) |
KR (1) | KR19980701276A (ja) |
CN (2) | CN1168095A (ja) |
AT (1) | ATE222757T1 (ja) |
AU (1) | AU688665B2 (ja) |
BR (1) | BR9606903A (ja) |
CA (1) | CA2209735C (ja) |
CZ (1) | CZ292226B6 (ja) |
DE (2) | DE122005000011I2 (ja) |
DK (1) | DK0721777T3 (ja) |
ES (1) | ES2181845T3 (ja) |
FI (1) | FI119354B (ja) |
FR (1) | FR10C0041I2 (ja) |
HU (1) | HU227306B1 (ja) |
LU (1) | LU91238I2 (ja) |
NL (1) | NL300180I2 (ja) |
NO (1) | NO317027B1 (ja) |
NZ (1) | NZ301500A (ja) |
PL (1) | PL187573B1 (ja) |
PT (1) | PT721777E (ja) |
RO (1) | RO118374B1 (ja) |
RU (1) | RU2163802C2 (ja) |
SI (1) | SI0721777T1 (ja) |
TR (1) | TR199700627T1 (ja) |
UA (1) | UA43385C2 (ja) |
WO (1) | WO1996021430A1 (ja) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
GB9613243D0 (en) * | 1996-06-25 | 1996-08-28 | Britannia Pharmaceuticals Ltd | Attention deficit hyperactive disorder |
AU9214498A (en) * | 1997-09-23 | 1999-04-12 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
US5902797A (en) * | 1997-11-10 | 1999-05-11 | Beth Israel Deaconess Medical Center | Nutritional supplement for use in the treatment of attention deficit |
CN1301164A (zh) * | 1998-04-09 | 2001-06-27 | 法玛西雅厄普约翰美国公司 | 神经病症的新疗法 |
US6586427B2 (en) | 1998-04-09 | 2003-07-01 | Pharmacia & Upjohn Company | Treatments for nervous disorders |
ES2351149T3 (es) * | 1998-11-09 | 2011-02-01 | Biogen Idec Inc. | Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica. |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6898455B2 (en) * | 1999-10-29 | 2005-05-24 | The Mclean Hospital Corporation | Method for providing optimal drug dosage |
US6400978B1 (en) | 1999-10-29 | 2002-06-04 | The Mclean Hospital Corporation | Method and apparatus for detecting mental disorders |
BR0108980A (pt) * | 2000-03-07 | 2003-06-03 | Lilly Co Eli | Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina |
US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US20040034106A1 (en) * | 2001-11-06 | 2004-02-19 | Read Holly Ann | Treatment of anxiety disorders |
WO2003049724A1 (en) * | 2001-12-11 | 2003-06-19 | Eli Lilly And Company | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
WO2004017977A2 (en) | 2002-08-23 | 2004-03-04 | Eli Lilly And Company | 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
WO2004103356A2 (en) * | 2003-05-15 | 2004-12-02 | Eli Lilly And Company | Treatment of emotional dysregulation |
WO2005011583A2 (en) * | 2003-07-28 | 2005-02-10 | Leslie Joe Dunaway | Treatment of allergic rhinitis and asthma |
CA2536161A1 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
EP1660064A2 (en) * | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
WO2005065673A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
WO2005115396A2 (en) * | 2004-05-27 | 2005-12-08 | Warner-Lambert Company Llc | Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders |
US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
CA2561387A1 (en) * | 2004-06-28 | 2006-01-12 | Teva Pharmaceutical Fine Chemicals S.R.L. | An isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards |
EP1768949A2 (en) * | 2004-07-22 | 2007-04-04 | Teva Pharmaceutical Fine Chemicals S.R.L. | Polymorphs of atomoxetiene hydrochloride |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
EP2417969A1 (en) | 2004-10-21 | 2012-02-15 | Aptalis Pharmatech, Inc. | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US7569729B2 (en) * | 2005-04-05 | 2009-08-04 | Teva Pharmaceutical Fine Chemicals S.R.L. | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
AU2006318476A1 (en) * | 2005-11-23 | 2007-05-31 | Auspex Pharmaceuticals, Inc. | Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity |
JP2009518337A (ja) | 2005-12-07 | 2009-05-07 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | 皮質カテコールアミン作動性神経伝達のモジュレーターとしての二置換フェニルピペリジン |
US20080020387A1 (en) * | 2006-03-31 | 2008-01-24 | Lawrence Donald G | Biomarker-optimized adhd treatment |
US20080146675A1 (en) * | 2006-04-05 | 2008-06-19 | Eugenio Castelli | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
US20080031932A1 (en) * | 2006-08-04 | 2008-02-07 | Watson Laboratories, Inc. | Transdermal atomoxetine formulations and associated methods |
US20080145318A1 (en) * | 2006-12-13 | 2008-06-19 | Midha Kamal K | Atomoxetine formulations and associated methods |
WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
US20100069390A1 (en) * | 2008-09-05 | 2010-03-18 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
RU2395313C2 (ru) * | 2008-10-15 | 2010-07-27 | Татьяна Прохоровна Тетерина | Способ коррекции синдрома дефицита внимания и гиперактивности |
CA2782285A1 (en) | 2009-12-02 | 2011-06-09 | Luigi Mapelli | Fexofenadine microcapsules and compositions containing them |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
SG193587A1 (en) | 2011-03-23 | 2013-10-30 | Ironshore Pharmaceuticals & Dev Inc | Methods and compositions for treatment of attention deficit disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
AU2013217013B2 (en) | 2012-02-08 | 2017-04-20 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
PT2838510T (pt) | 2013-11-08 | 2016-11-23 | Lilly Co Eli | Solução de atomoxetina |
CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457121A (en) * | 1994-09-02 | 1995-10-10 | Eli Lilly And Company | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake |
ZA958725B (en) * | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
-
1995
- 1995-01-11 US US08/371,341 patent/US5658590A/en not_active Expired - Lifetime
-
1996
- 1996-01-04 CN CN96191412A patent/CN1168095A/zh active Pending
- 1996-01-04 RO RO97-01260A patent/RO118374B1/ro unknown
- 1996-01-04 NZ NZ301500A patent/NZ301500A/en not_active IP Right Cessation
- 1996-01-04 CN CNA2005100832846A patent/CN1781480A/zh active Pending
- 1996-01-04 JP JP8521732A patent/JPH10512262A/ja not_active Withdrawn
- 1996-01-04 PL PL96321273A patent/PL187573B1/pl unknown
- 1996-01-04 WO PCT/US1996/000091 patent/WO1996021430A1/en not_active Application Discontinuation
- 1996-01-04 KR KR1019970704665A patent/KR19980701276A/ko not_active Application Discontinuation
- 1996-01-04 AU AU46938/96A patent/AU688665B2/en not_active Expired
- 1996-01-04 TR TR97/00627T patent/TR199700627T1/xx unknown
- 1996-01-04 BR BR9606903A patent/BR9606903A/pt unknown
- 1996-01-04 RU RU97113060/14A patent/RU2163802C2/ru active
- 1996-01-04 CA CA002209735A patent/CA2209735C/en not_active Expired - Lifetime
- 1996-01-04 HU HU9801283A patent/HU227306B1/hu active Protection Beyond IP Right Term
- 1996-01-04 CZ CZ19972145A patent/CZ292226B6/cs not_active IP Right Cessation
- 1996-01-09 ES ES96300157T patent/ES2181845T3/es not_active Expired - Lifetime
- 1996-01-09 SI SI9630534T patent/SI0721777T1/xx unknown
- 1996-01-09 DE DE200512000011 patent/DE122005000011I2/de active Active
- 1996-01-09 DK DK96300157T patent/DK0721777T3/da active
- 1996-01-09 DE DE69623141T patent/DE69623141T2/de not_active Expired - Lifetime
- 1996-01-09 AT AT96300157T patent/ATE222757T1/de active
- 1996-01-09 EP EP96300157A patent/EP0721777B1/en not_active Expired - Lifetime
- 1996-01-09 PT PT96300157T patent/PT721777E/pt unknown
- 1996-04-01 UA UA97073620A patent/UA43385C2/uk unknown
-
1997
- 1997-07-08 NO NO19973170A patent/NO317027B1/no not_active IP Right Cessation
- 1997-07-09 FI FI972922A patent/FI119354B/fi not_active IP Right Cessation
-
2005
- 2005-03-04 NL NL300180C patent/NL300180I2/nl unknown
- 2005-08-10 JP JP2005232408A patent/JP2005325139A/ja active Pending
-
2006
- 2006-05-03 LU LU91238C patent/LU91238I2/fr unknown
-
2010
- 2010-08-20 FR FR10C0041C patent/FR10C0041I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005325139A (ja) | 注意欠損/多動障害治療用の医薬を製造するためのトモキセチンの使用 | |
US6046193A (en) | Treatment of attention-deficit/hyperactivity disorder | |
Grünbaum | The placebo concept in medicine and psychiatry1 | |
Jones et al. | Effects of atropine on cardiac rhythm in conscious and anesthetized man | |
EA000856B1 (ru) | Способ лечения синдрома дефицита внимания/гиперактивности | |
Grant | Psychopharmacology in childhood emotional and mental disorders | |
Toolan | Therapy of depressed and suicidal children | |
Cole et al. | Physostigmine reversal of dysarthria and delirium after iatrogenic atropine overdose from a dental procedure | |
Little | Hazards of drug dependency among physicians | |
TW201117813A (en) | Role of N-2-hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury | |
Siegel | Bulimia, tricyclic antidepressants, and mania | |
Hameed et al. | Intravenous Lipid Emulsion Therapy In Paediatric Poisoning | |
MEADOR-WOODRUFF et al. | SINGLE CASE STUDY: Profound Behavioral Toxicity due to Tricyclic Antidepressants | |
Wesson et al. | Drug crisis intervention: conceptual and pragmatic considerations | |
Hubbard et al. | Pharmacotherapy of drug abusers: Adjunctive psychopharmacologic management of nonopiate mixed substance abusers in an outpatient setting | |
MXPA97005117A (en) | Use of tomoxetine for the manufacture of a medicine for the treatment of the disorder of deficitde the attention / hyperactivi | |
NEWMAN et al. | Imipramine as a psychoto-mimetic drug in borderline schizophrenics | |
KRAUS | Dr. Kraus Replies | |
Bosley et al. | Toxic shock syndrome after minor dermatological surgery: Authors' reply | |
Richards et al. | Phencyclidine psychosis | |
Schopbach | Anxiety And Its Pharmacologic Control | |
Bowes | Guillain-Barré Syndrome | |
Mascia | Psychotropic agents in the management of chronic asthmatic children | |
Naidu | Modern therapy in depression | |
DeVane et al. | Use of psychoactive drugs in children |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090407 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090707 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090805 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090810 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090907 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090910 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090917 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20091015 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20091015 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100720 |